Stock Price & Analysis

Based on the recent data and market analysis, here is a direct assessment of BMY stock:

Technical Analysis:

• BMY is showing a short-term uptrend with recent price action moving from $47 to around $49.74, forming higher lows and higher highs
• RSI-14 at 45.16 indicates neutral momentum, not showing overbought or oversold conditions
• MACD is slightly bearish with -0.66, suggesting some downward pressure

Recent Developments:

• CEO Christopher S. Boerner recently purchased 2,000 shares for approximately $110,096, demonstrating insider confidence
• The company received a high rating of 87% from Validea's Multi-Factor Investor model
• Truist Financial maintained a Buy rating with a $65 price target, suggesting potential upside

Institutional Activity:

• Strong institutional interest with 1,111 institutions adding positions while 1,125 reducing in the last quarter
• Congressional trading shows 2 purchases and 0 sales in past 6 months

Market Sentiment:

• Wall Street consensus is "Moderate Buy" based on 7 Strong Buy, 17 Hold, and 1 Strong Sell ratings
• Mean price target of $60.09 indicates a modest 1.6% upside potential, with street-high target at $73 suggesting 23.4% upside

Recommendation: SELL

• Despite positive insider buying and analyst ratings, technical indicators suggest weakness
• Current price action shows vulnerability to further downside
• Consider waiting for stronger technical confirmation before entering new positions

Based on the provided data and recent market developments, here is the price prediction analysis for BMY stock in 2025:

Technical Analysis

The stock is currently showing bearish momentum with RSI at 45.16 and MACD at -0.66, indicating downward pressure. The stock is trading below its 20-day SMA of $57.39, suggesting short-term weakness.

Fundamental Drivers

According to recent earnings reports, BMY faces several key factors that will influence its 2025 price:

1. Revenue Guidance:

• Management projects 2025 revenue of $45.5 billion, below analyst consensus of $46.27 billion
• Legacy portfolio expected to decline 18-20% due to generic competition
• Growth portfolio showing strong momentum with 21% YoY growth

2. Cost Optimization:

• Additional $2 billion in cost savings targeted by 2027
• $1 billion in savings expected in 2025

3. Pipeline Progress:

• Multiple late-stage pipeline readouts expected in 2025-2026
• Strong performance from new products like Reblozyl (+71% growth) and Breyanzi (+125% growth)

2025 Price Prediction

Based on the technical and fundamental analysis:

Base Case ($58-60): Most likely scenario (60% probability)

• Growth portfolio continues strong performance
• Cost savings partially offset generic impacts
• Pipeline advances as expected

Bullish Case ($62-65): Lower probability (20%)

• Better-than-expected growth portfolio performance
• Pipeline catalysts exceed expectations
• Successful integration of recent acquisitions

Bearish Case ($52-55): Moderate probability (20%)

• Deeper generic erosion than expected
• Pipeline setbacks
• Market multiple compression

Key Price Levels to Watch

• Support: $51.43 (Fibonacci S3)
• Resistance: $59.77 (Fibonacci R3)

The most likely scenario points to BMY trading in the $58-60 range by end of 2025, representing moderate upside from current levels, driven by growth portfolio momentum and cost optimization efforts offsetting generic pressures.

The S1 support level for BMY Stock is $54.02 ,The R1 resistant level for BMY Stock is $58.91.

As of the end of day on 2025-02-26, the price of BMY Stock was $58.06.

The target price for BMY Stock according to analyst rating is 60.54, with the highest price target at 70.00 and the lowest at 39.00. Analysts have a Moderate Buy rating on BMY Stock overall.

The market cap of BMY is $118.1B.

Based on the comprehensive financial data and recent market analysis, BMY is currently undervalued. The stock trades at a P/E ratio of 13.29x, significantly below its historical average and industry peers. Net income increased by 26.8% from $6.3B in 2022 to $8.0B in 2023, while maintaining a healthy gross margin of 56.34%. Recent insider purchases, including CEO Christopher Boerner's acquisition of 2,000 shares, signal management's confidence in the company's prospects.

The company's growth portfolio revenue increased by 21%, driven by strong performance from key drugs like Reblozyl, Breyanzi, and Camzyos. Additionally, BMY has identified $2 billion in cost savings by 2027, demonstrating commitment to operational efficiency. The stock's current technical indicators show RSI at 45.16, suggesting it's neither overbought nor oversold, with strong support at the $51.32 level.

The recent FDA approval of Cobenfy and promising pipeline developments provide potential catalysts for future growth. With a 2025 revenue target of $45.5 billion and expanded cost-saving initiatives, BMY presents a compelling value opportunity at current price levels.

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Based on the provided data and market analysis, here's a projection for Bristol-Myers Squibb (BMY) stock price in 2030:

BMY stock is projected to reach approximately $85-90 by 2030, driven by its robust growth portfolio expansion and $2 billion cost-saving initiatives through 2027. The company's strategic focus on innovative medicines and pipeline advancements, particularly in oncology and immunology segments, coupled with strong financial discipline, supports this growth trajectory despite near-term generic pressures on legacy products.

BMY has a total of 34100 employees.